RR-1752 / Icahn School of Medicine at Mount Sinai - LARVOL DELTA

A Novel Dual Kinase Inhibitor for the Treatment of Chronic Graft Vs. Host Disease (ASH 2023) - "Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, and belumosudil, a ROCK2 inhibitor, are both approved after two previous lines of therapy. We tested RR- RR-1752 a single digit nM dual ROCK/AURK inhibitor in a mouse model of severe cGVHD...Further studies are ongoing to assess higher dose levels and dose schedule effects in the severe cGVHD mouse model. Additional studies to compare effects on cGVHD to ruxolitinib and belumosudil and in combination with those standard of care therapies need to be conducted."

Alopecia • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology

A Dual-Specific Inhibitor of Rock/Aurk, RR-1752, for Primary Myelofibrosis (ASH 2023) - "Dose optimization of RR-1752 alone and in combination with ruxolitinib in the HEL-92.1.7 IV dissemination model as well as testing in the hMPL-W515L-evoked myelofibrosis model is ongoing. Conventional treatments for MF have largely focused on symptom management but RR-1752 treatment could result not only in beneficial symptom improvement but also important disease modifying potential by inhibiting JAK-STAT signaling, cell cycle progression and targeting dysregulated MKs."

Fibrosis • Immunology • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • CALR • CD34 • IL2 • JAK2 • TP53